Status:

UNKNOWN

Efficacy of Percutaneous Electrolysis in the Treatment of Achilles Tendinopathy

Lead Sponsor:

Maimonides University

Conditions:

Achilles Tendinopathy

Eligibility:

All Genders

18-65 years

Phase:

NA

Brief Summary

Achilles tendinopathy (AT) is one of the most reported myotendinous pathologies due to overuse in the literature. In the general adult population, its incidence is 2.35 cases per 1,000 patients, with ...

Eligibility Criteria

Inclusion

  • Presence of symptoms in one or both Achilles tendons with a minimum duration of two months. In case the symptoms are bilateral, the intervention or placebo will only be administered and its results evaluated- in the limb with greater symptomatology. If it is not possible to differentiate which one presents greater pain, the right Achilles tendon will be chosen.
  • Spontaneous pain of at least three points measured by a visual analog scale (VAS), reproducible by palpation between 2 and 6 cm above the insertion of the Achilles tendon in the calcaneal bone.
  • Evidence of tendinopathy by MRI.
  • Presence of post-static dyskinesia.
  • Willingness to not perform additional treatments (such as footwear modifications, physical therapy, orthotics, injections, or surgery) for Achilles tendon pain during the conduct of the trial.
  • Willingness to attempt to discontinue self-administration of medications (NSAIDs) for pain relief Achilles tendon(s) pain for at least 14 days prior to baseline assessment and during the course of the trial.

Exclusion

  • Presence or suspicion of pregnancy.
  • Previous surgical intervention on the AT in the symptomatic leg(s)
  • Total or partial rupture in the symptomatic AT
  • Chronic ankle instability, in the foot with symptomatic tendon(s).
  • Pathologies that can derive in pain in the region of the AT without being proper of the picture. (e.g.: osteoarthritis, impingement syndromes).
  • Presence of arthritis or any metabolic or endocrine disorder (type 1 or 2 diabetes).
  • Psychological disorders.
  • Oncologic history.
  • Treatment with quinolones or fluoroquinolones during the last two years.
  • Treatment with statins for the control of hypercholesterolemia for more than two months
  • Treatments within or at the periphery of the Achilles tendon, with anesthetics, corticosteroids or any other pharmacological agent during the last three months.
  • Needle phobia
  • Allergy to metal

Key Trial Info

Start Date :

July 1 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2025

Estimated Enrollment :

102 Patients enrolled

Trial Details

Trial ID

NCT05301959

Start Date

July 1 2023

End Date

December 1 2025

Last Update

August 1 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Maimonides University

Buenos Aires, Buenos Aires F.D., Argentina, 1405